BRIEF-Ultragenyx initiates phase 3 study of UX007 in patients with disabling movement disorders

* Ultragenyx initiates global phase 3 study of UX007 in

GLUT1 DS patients with disabling movement disorders

Source text for Eikon:

Further company coverage:

Read more